BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33849639)

  • 1. Composite lymphoma of T-cell rich, histiocyte-rich diffuse large B-cell lymphoma and nodular lymphocyte predominant Hodgkin lymphoma: a case report.
    Esper A; Alhoulaiby S; Zuhri Yafi R; Alshehabi Z
    J Med Case Rep; 2021 Apr; 15(1):163. PubMed ID: 33849639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature.
    Zheng SM; Zhou DJ; Chen YH; Jiang R; Wang YX; Zhang Y; Xue HL; Wang HQ; Mou D; Zeng WZ
    World J Gastroenterol; 2017 Jun; 23(24):4467-4472. PubMed ID: 28706431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
    Chen DB; Wang Y; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Schuhmacher B; Bein J; Rausch T; Benes V; Tousseyn T; Vornanen M; Ponzoni M; Thurner L; Gascoyne R; Steidl C; Küppers R; Hansmann ML; Hartmann S
    Haematologica; 2019 Feb; 104(2):330-337. PubMed ID: 30213827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis.
    Churchill HR; Roncador G; Warnke RA; Natkunam Y
    Hum Pathol; 2010 Dec; 41(12):1726-34. PubMed ID: 20825974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
    Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma.
    Park HC; Jung SH; Ahn JS; Kim MY; Yang DH; Kim YK; Kim HJ; Lee JJ
    Case Rep Oncol; 2012 May; 5(2):413-9. PubMed ID: 22949903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
    Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
    Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
    Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response.
    Van Loo P; Tousseyn T; Vanhentenrijk V; Dierickx D; Malecka A; Vanden Bempt I; Verhoef G; Delabie J; Marynen P; Matthys P; De Wolf-Peeters C
    Haematologica; 2010 Mar; 95(3):440-8. PubMed ID: 19797726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of the Flow Cytometric Findings in Classic Hodgkin Lymphoma, Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte-Rich Large B Cell Lymphoma.
    Ally F; Gajzer D; Fromm JR
    Clin Lab Med; 2023 Sep; 43(3):427-444. PubMed ID: 37481321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD5+ T-cell/histiocyte-rich large B-cell lymphoma.
    Chang CC; Bunyi-Teopengco E; Eshoa C; Chitambar CR; Kampalath B
    Mod Pathol; 2002 Oct; 15(10):1051-7. PubMed ID: 12379751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
    Niino D; Ohsaki K; Arakawa F; Watanabe J; Kimura Y; Kiyasu J; Takeuchi M; Miyoshi H; Yoshida M; Sugita Y; Ohshima K; Okamura T
    Pathol Int; 2011 Jun; 61(6):363-8. PubMed ID: 21615612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.
    Boudová L; Torlakovic E; Delabie J; Reimer P; Pfistner B; Wiedenmann S; Diehl V; Müller-Hermelink HK; Rüdiger T
    Blood; 2003 Nov; 102(10):3753-8. PubMed ID: 12881319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapsed nodular lymphocyte-predominant Hodgkin lymphoma presenting as severe paraneoplastic hepatitis: a case report.
    Deacon AJ; Goetz NN; Weber N; Clouston A; Gonsalkorala E; Baskerville C; Leggett B
    J Med Case Rep; 2023 Jun; 17(1):269. PubMed ID: 37386640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
    Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of lymphoma with respect to pathologic classification: updates and controversies].
    Zhu J; Song YQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):724-7. PubMed ID: 20079009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.